Ardelyx enters the back half of August with a stock down 25% in a month and a Street that still formally likes the company — but keeps cutting what it's willing to pay for it.
The catalyst was the August 6 earnings print. The stock fell 18.5% the next day and extended the move to -20% over the following five sessions. That single event re-set the price from around $4.80 to the current $3.92, leaving the shares down roughly 25% in a month. The next earnings date is October 29 — the market will be calibrating commercial traction on Ibsrela and Xphozah for the next ten weeks with that print as the target.
The analyst picture captures the post-earnings mood precisely: everyone still says Buy, but almost everyone just cut their target. Piper Sandler trimmed to $15 from $16 on August 17 while keeping Overweight. Citigroup moved to $11 from $14 on August 10. TD Cowen and BTIG both reduced targets on August 7, to $10 and $14 respectively, each holding their Buy ratings. Wedbush has reiterated Outperform this week at $9 — the most conservative of the bulls and the closest to where the stock actually trades. The consensus target is $13, implying more than 230% upside from $3.92. That gap reflects genuine uncertainty rather than conviction: the Street has not turned bearish on the story, but the cadence of target cuts signals growing caution about the commercial execution timeline. The bull case rests on Ibsrela and Xphozah becoming meaningful revenue drivers in their respective markets; the bear case is that pricing pressure and competition slow uptake further, making those revenue targets harder to hit.
Positioning in the borrow market is notably relaxed given the stock's selloff. Short interest is elevated at nearly 11% of the free float — a meaningful level for a small biotech — and has crept up about 4% over the past month as new shorts pressed the post-earnings weakness. But the borrow itself remains almost entirely unconstrained. Availability is close to 963% of short interest, meaning the lending pool holds roughly nine shares available for every one currently borrowed. Cost to borrow is running below 0.5%, well within normal range. The picture is of a stock where bears are present but not crowded: there is ample room for short interest to build further without any mechanical squeeze pressure developing. Options positioning has shifted sharply in the other direction. The put/call ratio is at 1.13, near its 52-week high of 1.15 and well above its 20-day average of 0.58 — a 1.6 standard-deviation move toward defensive hedging. That contrast is worth noting: the borrow market is loose and uncrowded, while options traders have pivoted hard to downside protection since the earnings miss.
One wrinkle on the institutional side is worth flagging. Aigh Capital Management opened a new position of 3.2 million shares as of June 30, adding meaningful conviction at levels now well above the current price. BlackRock added 2.3 million shares as of July 31, maintaining its position as the largest holder at over 9% of shares outstanding. Millennium Management, on the other hand, trimmed by 3.6 million shares in Q2. Insider activity has been uniformly one-directional: CEO Michael Raab sold in May, June, and July, including two tranches totalling roughly 83,000 shares in June and July at prices between $5.06 and $5.67 — well above where the stock now trades. Those sales were on a pre-arranged schedule, but the direction adds no positive signal.
What to watch into October 29 is whether prescription trends for Ibsrela and Xphozah show any sequential improvement — because the current analyst targets, even after the round of post-earnings cuts, require a meaningful acceleration in commercial uptake to become credible.
See the live data behind this article on ORTEX.
Open ARDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
